STUDY OF SOME THERAPEUTIC STRATEGIES FOR DIABETIC PATIENTS AFFECTED FROM COVID 19

Soumya Tripathi Assistant Professor, NIET Pharmacy Institute, Plot no. 19, Knowledge park-2, Greater Noida,
Ketki Rani Assistant Professor, NIET Pharmacy Institute, Plot no. 19, Knowledge park-2, Greater Noida,
Richa Shakya Assistant professor, NIET Pharmacy Institute, Plot no. 19, Knowledge park-2, Greater Noida
Sonia Chauhan Assistant professor, NIET Pharmacy Institute, Plot no. 19, Knowledge park-2, Greater Noida
Dr.Avijit Mazumder Director, NIET Pharmacy Institute, Plot no. 19, Knowledge park-2, Greater Noida, 201310
Dr.Rupa Mazumder Dean, NIET Pharmacy Institute, Plot no. 19, Knowledge park-2, Greater Noida, 201310

Abstract

One of history's greatest human crises is the 2019 Coronavirus Pandemic (COVID-19). Patients with diabetes and related comorbidities have a higher chance of developing COVID-19 problems and dying. The severity of the condition, which makes it more vulnerable to severe symptoms and higher mortality rates in patients, especially those with high blood pressure, cardiovascular illnesses, obesity or diabetes, is causing increasing concern about the consequences of this pandemic. In the early stages of research, it is not apparent if diabetes, or diabetes-related comorbidities, or treatment strategies, lead to a COVID-19 result that is more severe. SARS-CoV-2, which may impair diabetics, can be combated by identifying a novel therapeutic strategy. Diabetic and COVID-19 connection: Potential pathogenic mechanisms and therapeutic suggestions It is impossible to draw definite conclusions based on the currently available insufficient data.

Keywords:

COVID-19, SARS-CoV-2, Diabetes, Therapeutic treatment


Full Text:

PDF


References



References 1. Varghese E, Samuel SM, Liskova A, Kubatka P, Bu¨sselberg D (2021), Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing, https://doi.org/10.1371/journal.ppat.1009634 2. Lei Li, Ranran Li, Zhixiong Wu, Xianghong Yang, Mingyan Zhao, Jiao Liu and Dechang Chen (2020), “Therapeutic strategies for critically ill patients with COVID-19”, Li et al. Ann. Intensive Care (2020) 10:45 https://doi.org/10.1186/s13613-020-00661-z 3. Soo Lim, Jae Hyun Bae, Hyuk-Sang Kwon and Michael A. Nauck (2021), “COVID-19 and diabetes mellitus: from pathophysiology to clinical management”, Endocrinology, Volume 17. 4. Alireza Abdi, Milad Jalilian, Pegah Ahmadi Sarbarzeh, Zeljko Vlaisavljevic (2020), “Diabetes and COVID-19: A systematic review on the current evidences”, Diabetes Research and Clinical Practice, https://doi.org/10.1016/j.diabres.2020.108347. 5. Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Dario Giugliano and Katherine Esposito (2020), “Treating type 2 diabetes in COVID-19 patients: the potential benefts of injective therapies”, Longo et al. Cardiovasc Diabetol, https://doi.org/10.1186/s12933-020-01090-9 6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (2020), Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.;395(10223):497-506. Epub 2020/01/28. doi: 10.1016/S0140-6736(20)30183-5. PubMed PMID: 31986264. 7. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. (2020), The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. Epub 2020/03/10. doi: 10.7326/M20-0504. 8. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11. Epub 2020/03/15. doi: 10.1186/s40779-020-00240-0. 9. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. Epub 2020/03/19. doi: 10.1186/s40249-020-00646-x. 10. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020. Epub 2020/03/17. doi: 10.1016/j.ijid.2020.03.017. 11. Wang A, Zhao W, Xu Z, Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020:108118. Epub 2020/03/18. doi: 10.1016/j.diabres.2020.108118. 12. Ursini F, Ciaffi J, Landini MP, Meliconi R. COVID-19 and diabetes: Is metformin a friend or foe? Diabetes Res Clin Pract. 2020; 164:108167. https://doi.org/10.1016/j.diabres.2020.108167. 13. Kruglikov IL, Shah M, Scherer PE. Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral–bacterial interactions. Elife. 2020; 9:e61330. https://doi.org/10.7554/ eLife.61330 14. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020; 127:104354. https://doi.org/10.1016/j. jcv.2020.104354 15. Lalau JD, Al-Salameh A, Hadjadj S, Goronflot T, Wiernsperger N, Pichelin M, et al. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. 2020; 47(5):101216. \ 16. Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G, Cacopardo B. Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? Eur Rev Med Pharmacol Sci. 2020;24(5):2781-3. Epub 2020/03/21. doi: 10.26355/eurrev 17. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020:1-13. Epub 2020/02/29. doi: 10.1056/NEJMoa2002032. 18. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. 19. Organization WH. clinical-management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected-interim guidance. Published January 28, 2020. 20. Qiu H, Tong Z, Ma P, et al. Intensive care during the coronavirus epidemic. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-05966-y. 21. Hui DS, Azhar I, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest, novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2019;2020(91):264–6. 22. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. 23. Yu YX, Sun L, Yao K, et al. Consideration and prevention for the aerosol transmission of 2019 novel coronavirus. Zhonghua Yan Ke Za Zhi. 2020;56:E008. 24. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2004973. 25. Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020. https://doi.org/10.5582/bst.2020.01030. 26. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 2020 S2213-2600(20)30116-8. doi: 10.1016/S2213-2600(20)30116-8. 27. Gupta R., Ghosh A., Singh A.K., Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab. Syndr. 2020;14:211–212. 28. Zhang J.J., Dong X., Cao Y.Y., Yuan Y.D., Yang Y.B., Yan Y.Q., Akdis C.A., Gao Y.D. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 doi: 10.1111/all.14238. 29. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 doi: 10.1007/s00134-020-05991-x. 30. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020 doi: 10.1001/jama.2020.2648 31. Cao J., Hu X., Cheng W., Yu L., Tu W.J., Liu Q. Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intensive Care Med. 2020 doi: 10.1007/s00134-020-05987-7. 32. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., Yu T., Wang Y., Pan S., Zou X., Yuan S., Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020 S2213-2600(20)30079-5 doi: 10.1016/S2213-2600(20)30079-5. 33. Pearson-Stuttard J., Blundell S., Harris T., Cook D.G., Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2016;4:148–158. 34. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., Bi Z., Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020 doi: 10.1007/s00392-020-01626-9. 35. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020 S1201-9712(20)30136-3 doi: 10.1016/j.ijid.2020.03.017. 36. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., Bi Z., Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020 doi: 10.1007/s00392-020-01626-9. 37. F. Bonnet and A. J. Scheen, “Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease,” Diabetes & Metabolism, vol. 44, 38. Bose S, Adapa S, Aeddula NR, Roy S, Nandikanti D, Vupadhyayula PM, Naramal S, Gayam V, Muppidi V, Konala VM. Medical management of COVID-19: evidence and experience. J Clin Med Res. 2020;12(6):329–43. 39. Dagens A, Sigfrid L, Cai E, Lipworth S, Cheng V, Harris E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ. 2020;369:m1936. 40. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020. https://doi.org/10.1016/j.jaci.2020.04.006. 41. Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020. https://doi.org/10.1038/s41574-020-0353-9.Advanceonlinepublication. 42. Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care. 2020;43(7):1382–91. https://doi.org/10.2337/dc20-0598. 43. Cariou B, Hadjadj S, Wargny M, et al. 2020; Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia.;63(8):1500–15. https://doi.org/10.1007/s00125-020-05180-x. 44. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, Knighton P, Holman N, Khunti K, Sattar N, Wareham NJ. Type 1 and type 2 diabetes and COVID-19 related mortality in England: a whole population study (5/17/2020). SSRN: https://ssrn.com/abstract=3605225 or https://doi.org/10.2139/ssrn.3605225. 45. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.4683. 46. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. https://doi.org/10.1183/13993003.00547-2020. 47. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Bio-Med. 2020;91(1):157–60. https://doi.org/10.23750/abm.v91i1.9397. 48. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020. https://doi.org/10.1001/jama.2020.1097.publishedonlineJan30. 49. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. Epub 2020/02/08. doi: 10.1001/jama.2020.1585. 50. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020. Epub 2020/02/25. doi: 10.1001/jama.2020.2648. 51. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. J Med Virol. 2020. Epub 2020/02/28. doi: 10.1002/jmv.25727. 52. Pearson-Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2016;4(2):148-58. Epub 2015/12/15. doi: 10.1016/S2213-8587(15)00379-4. 53. McDonald HI, Nitsch D, Millett ER, Sinclair A, Thomas SL. New estimates of the burden of acute community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using linked electronic health records. Diabet Med. 2014;31(5):606- 14. Epub 2013/12/18. doi: 10.1111/dme.12384. PubMed PMID: 24341529; 54. Wang A, Zhao W, Xu Z, Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020:108118. Epub 2020/03/18. doi: 10.1016/j.diabres.2020.108118. 55. Zhou J, Tan J. Diabetes patients with COVID-19 need better care. Metabolism. 2020:154216. Epub 2020/03/30. doi: 10.1016/j.metabol.2020.154216. 56. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020. Epub 2020/03/07. doi: 10.1038/s41569-020-0360-5. 57. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(0):E004. Epub 2020/03/04. doi: 10.3760/cma.j.cn112148-20200220-00105. 58. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARSCoV-2. Antimicrob Agents Chemother. 2020. Epub 2020/03/25. doi: 10.1128/AAC.00483-20. 59. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. Epub 2020/02/20. doi: 10.5582/bst.2020.01047. 60. Hussain, A., Bhowmik, B., & do Vale Moreira, N. C. (2020). COVID-19 and diabetes: Knowledge in progress. Diabetes research and clinical practice, 162, 108142. https://doi.org/10.1016/j.diabres.2020.108142

Refbacks

  • There are currently no refbacks.